The Simple Truth
Why this exists and what it’s supposed to do.
GHK-Cu exists because copper is needed to repair tissue, and this peptide is how the body carries it.
GHK is a three-amino-acid sequence found naturally in human plasma that binds copper, which the enzymes that build collagen require. Plasma levels fall substantially with age.
What it is supposed to do: rebuild skin — more collagen, firmer texture, faded fine lines, faster wound healing. It is mostly used topically for skin aging, which is why it appears in cosmetic products.
Of the skin peptides, this has some of the better supporting research, though much of it is cell and animal work.
Separate the complex from the promise
GHK-Cu refers to a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Its research history is often compressed into broad claims about healing, skin rejuvenation or aging. A more useful reading preserves the experimental setting. Which cells or animals were studied, how the material was delivered and what was actually measured determine the scope of the finding.
The copper complex, a finished cosmetic formulation and an injected research product are not automatically equivalent interventions. Even where the chemical name matches, concentration, formulation, exposure and route can differ. This profile focuses on two foundational primary papers rather than presenting every proposed mechanism as a demonstrated human benefit or claiming a complete systematic review.
The collagen paper used fibroblast cultures
A 1988 FEBS Letters paper reported stimulation of collagen synthesis in fibroblast cultures exposed to the tripeptide-copper complex. That is a cell experiment. It is relevant to understanding a biological response under laboratory conditions, but it does not contain a clinical trial showing that people look younger or recover faster after using a particular product.
Collagen synthesis is an experimental endpoint, not a stand-in for every aspect of skin function or appearance. The result cannot independently establish penetration through intact skin, an effective finished formulation, systemic benefit or long-term safety. Human-derived cells, where used in a laboratory, remain cell evidence; their origin does not turn a culture experiment into a human treatment study.
The wound paper studied a specific rat model
A 1993 Journal of Clinical Investigation paper examined connective-tissue accumulation in rat experimental wounds. The investigators administered the complex locally to wound chambers and measured tissue-related endpoints. This adds in-vivo evidence in a controlled model, which is a different level of investigation from a cell dish but still not a clinical trial in people.
A wound chamber is not intact human facial skin, and local exposure in an experimental wound is not the same as a systemic injection. These distinctions do not make the animal result worthless. They identify what further work would be needed before applying it to a different use. Statements about predictable whole-body regeneration or clinical anti-aging effects go beyond the study's design.
What a responsible evidence summary should say
The defensible summary is that GHK-Cu has mechanistic and preclinical observations worth examining. It is not that every marketed benefit has been clinically established. To assess a more specific claim, look for a controlled human study of the relevant finished formulation, population, route and outcome. A paper about collagen in culture should be described as such wherever it appears in a product narrative.
The same caution applies to blends. Adding GHK-Cu to other compounds does not carry these results into the mixture or establish synergy, stability or safety. Analytical identity and quality testing answer different questions from clinical performance. This guide therefore supplies no mixing or injection regimen, makes no supplier recommendation and does not use a foundational laboratory paper as a substitute for clinical evidence.